TY  - GEN
AU  - Harousseau,Jean-Luc
AU  - Attal,Michel
AU  - Avet-Loiseau,Hervé
AU  - Marit,Gerald
AU  - Caillot,Denis
AU  - Mohty,Mohamad
AU  - Lenain,Pascal
AU  - Hulin,Cyrille
AU  - Facon,Thierry
AU  - Casassus,Philippe
AU  - Michallet,Mauricette
AU  - Maisonneuve,Hervé
AU  - Benboubker,Lotfi
AU  - Maloisel,Frédéric
AU  - Petillon,Marie-Odile
AU  - Webb,Iain
AU  - Mathiot,Claire
AU  - Moreau,Philippe
TI  - Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
SN  - 1527-7755
PY  - 2010///1108
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Boronic Acids
KW  - Bortezomib
KW  - Chemotherapy, Adjuvant
KW  - Chi-Square Distribution
KW  - Dexamethasone
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Europe
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - diagnosis
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Protease Inhibitors
KW  - Pyrazines
KW  - Stem Cell Transplantation
KW  - Time Factors
KW  - Transplantation, Autologous
KW  - Treatment Outcome
KW  - Vincristine
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1200/JCO.2009.27.9158
ER  -